Gantenerumab

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease. A phase I clinical trial has been conducted in 2006/07.

Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries.